title: Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus.
abstract: Treatment modalities in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are many and varied, although level 1 evidence supporting their use is limited. To date, only 2 systematic reviews exist to support the use of different treatment modalities to control this group of conditions. Overall, within the literature, the quality of trials comparing treatment modalities is poor. Cohort sizes are small, methodologies are varied, and standardized outcome measurements are lacking. The authors aim to present a comprehensive view of the level 1 evidence that exists for common treatment modalities used in PV and PF.
authors.affiliation: St George Hospital, Gray Street, Kogarah, Sydney, NSW 2217, Australia.
authors.forename: John W
authors.initials: JW
authors.lastname: Frew
authors.forename: Linda K
authors.initials: LK
authors.lastname: Martin
authors.forename: Dédée F
authors.initials: DF
authors.lastname: Murrell
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008516:Medicine, Chinese Traditional; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010392:Pemphigus / Q000188:drug therapy* / Q000628:therapy; D010431:Pentoxifylline / Q000627:therapeutic use; D010956:Plasmapheresis; D016032:Randomized Controlled Trials as Topic; D012460:Sulfasalazine / Q000627:therapeutic use; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D003879:Dermatologic Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D004815:Epidermal Growth Factor; C117268:pimecrolimus; D016572:Cyclosporine; D003520:Cyclophosphamide; D003622:Dapsone; D009173:Mycophenolic Acid; D001379:Azathioprine; D010431:Pentoxifylline; D016559:Tacrolimus